在急性移植与宿主疾病临床试验中,基于生物标志物的策略和挑战
Nikolaos Katsivelos1, Ioannis E Louloudis2, Nikolaos Spyrou2
1Department of Medicine, Jacobi Medical Center/North Central Bronx Hospital, Albert Einstein College of Medicine, Bronx, NY, USA.
International journal of hematology
|December 13, 2025
概括
生物标志物改善了干细胞移植后急性移植对宿主疾病 (GVHD) 的风险预测. 由生物标志物指导的策略可以实现个性化治疗,减少并发症并改善患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 移植医学 移植医学
背景情况:
- 急性移植对宿主疾病 (GVHD) 是异性造血干细胞移植后的一种严重并发症.
- 目前基于临床症状的风险分层方法对治疗反应和长期结果的预后准确性有限.
研究的目的:
- 突出生物标志物的作用,以提高急性GVHD的预测和预后精度.
- 讨论生物标志物引导的策略如何可以个性化治疗并改善患者的治疗结果.
主要方法:
- 对急性GVHD预测和预后生物标志物的现有文献的审查.
- 对生物标志物指导策略对患者分层和治疗强度的影响分析.
- 检查包含生物标志物数据的临床试验设计.
主要成果:
- 生物标志物有望提高急性GVHD风险分层的准确性.
- 以生物标志物为指导的方法可以早期识别高风险患者,从而及时进行干预,低风险患者则可接受不那么密集的治疗.
- 在一些研究中,基于生物标志物的个性化治疗策略与减少感染率和改善与GVHD相关的结果有关.
结论:
- 生物标志物驱动的策略为开发急性GVHD风险适应管理提供了一个有希望的框架.
- 生物标志物算法的持续验证和改进对于优化异质干细胞移植患者的结果至关重要.
更多相关视频
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
7.5K
10:29Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
Published on: August 29, 2012
16.1K
相关概念视频
01:22Bone Marrow Sampling and Transplants
801
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
801
01:40Cell-mediated Immune Responses
83.2K
Overview
83.2K